Penumbra IncPEN

Penumbra’s strongest current rail is the 10-Q for the period ending 2026-03-31: revenue of $374.8M, net income attributable to parent of $32.6M, operating income of $38.2M and diluted EPS of $0.82. That gives PEN a filed operating story before the reader gets anywhere near softer product language. Source: PEN 10-Q, SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1321732/000132173226000019/pen-20260331.htm.

The company story in the supplied evidence is medical technology with real products and real materials. Penumbra’s Artemis Neuro Evacuation Device is officially described as intended for controlled aspiration of tissue and/or fluid from the Ventricular System and/or Cerebrum, and the product page invites facilities to request a demonstration. The broader product rail also includes warnings such as not using automated high-pressure contrast injection equipment with the Penumbra Reperfusion Catheter because it may damage the device. Sources: Penumbra product pages, https://www.penumbrainc.com/products/artemis-neuro-evacuation-device/ and https://www.penumbrainc.com/products.

The balance-sheet and cash figures are material. The latest available SEC facts list assets of $1.90B, liabilities of $424.6M, stockholders' equity attributable to parent of $1.47B, cash and cash equivalents of $241.3M, net cash provided by operating activities of $87.0M, payments to acquire property, plant and equipment of $13.7M, inventory of $438.5M and an inventory increase of $9.0M, all for the 10-Q period ending 2026-03-31. The diluted share count was 39.5M shares. Source: PEN 10-Q, SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1321732/000132173226000019/pen-20260331.htm.

The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. The renderer may carry a chart rail elsewhere, but this JSON cannot pretend to see candles or levels that are not in the evidence. Sources: PEN SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1321732 and PEN submissions JSON, https://data.sec.gov/submissions/CIK0001321732.json.

The named developments are filing-heavy. On 2026-05-07, PEN filed 8-K and 425 materials saying a proposal to approve, on a non-binding, advisory basis, compensation that named executive officers will or may be eligible to receive in connection with the Merger was approved based on voting results. On 2026-05-29, the Form SD said certain thrombectomy, embolization and access products contain tin, tungsten and/or gold, and identified seven 3TG suppliers. Sources: SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1321732/000132173226000024/pen-20260506.htm, https://www.sec.gov/Archives/edgar/data/1321732/000132173226000025/pen-xspecialmeetingvoteres.htm and https://www.sec.gov/Archives/edgar/data/1321732/000132173226000027/penformsd2025.htm.

What remains unproven is just as important as what is filed. The evidence does not supply fresh guidance, current share-price action, product sales by line, customer adoption, regulatory approval news or a post-quarter earnings update. The cleanest next improvement would be another official filing or company release connecting the $374.8M revenue base, $438.5M inventory position and product rail to later demand and cash conversion.